10-Q: Artiva Biotherapeutics Q2 Loss Widens Amid Autoimmune Focus

Sentiment:

Quarterly Report 6 August 2025 4:13 PM

📋All filings for Artiva Biotherapeutics, INC

Artiva Biotherapeutics reported increased net losses and cash burn in Q2 2025, while strategically shifting its clinical focus to autoimmune diseases with its lead candidate AlloNK.

Delay expectedThe company completed its Phase 1/2 B-NHL clinical trial in July 2025 and decided to discontinue the remaining long-term follow-up period to focus resources on autoimmune indications, which represents a shift in development timelines for its oncology pipeline.The filing highlights general risks of clinical trials, including potential for substantial delays due to factors like patient enrollment, regulatory hurdles, manufacturing issues, or adverse events, which could impact the timely progression of current and future trials.

Capital raiseThe company explicitly states, 'We will need to obtain substantial additional funding to complete the development and any commercialization of our current and any future product candidates.'It expects to finance cash needs through 'public or private equity or debt financings or other capital sources, which may include our existing and any future strategic collaborations and other strategic arrangements with third parties.'The company warns that 'To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted.'

Worse than expectedNet loss increased to $41.6 million for the six months ended June 30, 2025, from $31.8 million in the prior year, indicating a worsening financial performance.Cash used in operating activities increased to $42.8 million from $28.8 million, reflecting a higher cash burn rate.The termination of the collaboration agreement with Affimed GmbH due to their insolvency is a negative operational development, as it removes a partner for a combination therapy.

Summary

Artiva Biotherapeutics, a clinical-stage biotechnology company, reported a net loss of $41.6 million for the six months ended June 30, 2025, compared to $31.8 million for the same period in 2024.
Cash used in operating activities increased to $42.8 million for the six months ended June 30, 2025, up from $28.8 million in the prior year period.
Research and development expenses rose significantly to $34.9 million for the six months ended June 30, 2025, from $23.5 million in 2024, primarily driven by increased costs for AlloNK's autoimmune clinical trials.
General and administrative expenses also increased to $10.1 million for the six months ended June 30, 2025, from $7.4 million in 2024, mainly due to increased headcount.
The company's cash, cash equivalents, and investments stood at $142.4 million as of June 30, 2025, with an accumulated deficit of $288.2 million.
The Phase 1/2 clinical trial of AlloNK in B-cell non-Hodgkin lymphoma (B-NHL) was completed in July 2025, with long-term follow-up discontinued to reallocate resources to autoimmune indications.
A global Phase 2a basket clinical trial for AlloNK in combination with rituximab for refractory rheumatoid arthritis (RA), Sjogren's disease, idiopathic inflammatory myopathies, and systemic sclerosis has been initiated, with the first patient treated in August 2025.
The collaboration agreement with Affimed GmbH was terminated in July 2025 following Affimed's insolvency filing in May 2025, with no fees payable or receivable due to termination.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to widening net losses, increased cash burn, and the termination of a key collaboration. While the strategic pivot to autoimmune diseases and progress in Phase 2a trials for AlloNK are positive clinical developments, the immediate financial performance and the inherent high risks of an early-stage biotech company with novel technology temper the overall outlook. The need for future capital raises and associated dilution are also significant concerns.

Positives

Initiation of a global Phase 2a basket clinical trial for AlloNK in multiple autoimmune indications, marking a significant step in clinical development.
First patient treated in the Phase 2a basket trial in August 2025, demonstrating progress in patient enrollment.
AlloNK received Fast Track designation from the FDA for lupus nephritis (February 2024) and relapsed/refractory B-NHL (January 2023), potentially expediting regulatory review.
Increased interest income to $3.4 million for the six months ended June 30, 2025, due to higher investment balances.

Negatives

Net loss widened to $41.6 million for the six months ended June 30, 2025, from $31.8 million in the prior year.
Cash used in operating activities increased to $42.8 million, indicating a higher cash burn rate.
Termination of the collaboration agreement with Affimed GmbH due to their insolvency, potentially impacting development plans for the combination therapy.
Discontinuation of long-term follow-up for the Phase 1/2 B-NHL clinical trial, shifting focus away from oncology indications.

Risks

Limited operating history and no products approved for commercial sale make it difficult to evaluate future success and viability.
Substantial additional funding will be required to complete development and commercialization, potentially causing dilution to stockholders.
The NK cell-based product candidate development approach is unproven, and commercial value or platform obsolescence is uncertain.
Novel technologies make predicting development time and cost, and obtaining regulatory approval, difficult.
Substantial dependence on the success of lead product candidate, AlloNK, which is in early clinical development, with other internally developed candidates in preclinical/discovery stages.
Current clinical data for NK cell therapies against autoimmune diseases are limited, raising uncertainties about therapeutic benefits and competitiveness against existing treatments.
Clinical trials are expensive, time-consuming, difficult to design and implement, and have uncertain outcomes, with potential for substantial delays.
Product candidates may cause serious adverse events or undesirable side effects, potentially delaying or preventing regulatory approval or limiting commercial profile.
Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to external factors.
Results from investigator-initiated trials (IITs) are not representative of company-sponsored trials and cannot be used for regulatory approval.
Affected patient populations for product candidates may be smaller than projected, impacting addressable markets.
International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, and prospects.
Reliance on collaboration agreements (e.g., with GC Cell) means prospects depend significantly on their success.
Manufacture of cell therapy products is novel, complex, and subject to multiple risks, including potential manufacturing problems or required process modifications.
Continued partial reliance on GC Cell for manufacturing increases supply risk, and own facility may encounter delays or quality issues.
Dependence on third parties for acquiring, shipping, and storing critical materials (cord blood units, cell banks, viral vectors) poses disruption, quality, damage, or loss risks.
Reliance on single-source suppliers for reagents and specialized materials/equipment, which may not be available on acceptable terms or at all.
Significant competition from other biotechnology and pharmaceutical companies, which could adversely affect operating results.
Substantial dependence on intellectual property rights licensed from GC Cell; loss of licenses could harm business.
Need to expand the organization, which may present challenges in managing growth and disrupt operations.
Future success depends on ability to retain key personnel and attract qualified personnel.
Information technology systems or data compromises could lead to adverse impacts, including operational interruptions and regulatory actions.
Business is subject to risks from pandemic and epidemic diseases.
Potential for litigation, government investigations, and enforcement actions.
Employees and independent contractors may engage in misconduct or improper activities.
Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
Changes in tax laws or regulations may adversely affect business.
Investor expectations regarding environmental, social, and governance (ESG) factors may impose additional costs and risks.
The trading price of common stock is likely to be volatile, leading to potential investment loss.
Executive officers, directors, and principal stockholders have significant control over matters submitted to stockholders for approval.
Future sales and issuances of securities, including under equity incentive plans and the Pledge 1% Movement commitment, may cause dilution or decrease stock price.
Reduced disclosure requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations.
No cash dividends anticipated in the foreseeable future, making capital appreciation the sole source of gain.
Delaware law and provisions in corporate documents could make a merger, tender offer, or proxy contest difficult.
Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
Operations concentrated in one location (California), exposing the company to risks from natural disasters.
Insurance policies may be inadequate or not cover all potential liabilities.
Increasing use of social media platforms presents new risks and challenges.

Future Outlook

The company expects to continue incurring significant losses as it advances product candidates through preclinical and clinical development and builds operations as a public company. Initial safety and translational data for AlloNK in autoimmune indications, along with the disclosure of the lead autoimmune indication, are expected by the end of 2025. Initial clinical response data for the lead autoimmune indication is anticipated in the first half of 2026 to inform registrational strategy. Existing cash, cash equivalents, and investments are projected to fund planned operations into the second quarter of 2027, but substantial additional funding will be required thereafter.

Management Comments

We believe the preliminary results from our Phase 1/2 clinical trial evaluating AlloNK in combination with rituximab in patients with B-NHL provide for a readthrough to autoimmune disease because efficacy in both diseases appears to be accomplished with a shared mechanism of action involving B-cell depletion in the periphery and in the lymphoid tissues, followed by an immunological reset and B-cell reconstitution.
We expect to report initial safety and translational data for AlloNK in combination with a mAb across multiple autoimmune indications from ongoing clinical trials, and disclosure of our lead autoimmune indication for further development, by the end of 2025, and to report initial clinical response data in the lead autoimmune indication from ongoing clinical trials with longer follow-up to inform registrational strategy in the first half of 2026.
We expect to continue to incur significant losses for the foreseeable future as we advance our current and future product candidates through preclinical and clinical development, continue to build our operations and transition to operating as a public company.
We expect that our research and development expenses will increase substantially in connection with our planned preclinical and clinical development activities in the near term and in the future.
We expect that our general and administrative expenses will increase substantially for the foreseeable future to support our continued research and development activities, pre-commercial preparation activities for our product candidates, and, if any product candidate receives marketing approval, commercialization activities.
We expect that we and GC Cell will be capable of providing and processing sufficient quantities of our product candidates to meet anticipated clinical trial demands cost-effectively.
We plan to continue to invest in our manufacturing capability and cryopreservation techniques to continuously improve our production and supply chain capabilities over time.

Industry Context

Artiva Biotherapeutics operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically within the novel field of NK cell-based therapies. There are currently no NK cell-based therapies approved for commercial use by any regulatory authority, nor are there any cell therapies approved for autoimmune diseases. The company's strategic shift to autoimmune indications positions it in a nascent but potentially high-growth area, drawing parallels to the success of autologous CAR T-cell therapies in B-cell depletion for autoimmune conditions. However, this also means facing increasing competition from numerous established cell therapy companies with oncology backgrounds that are now expanding into autoimmune disease development.

Comparison to Industry Standards

The company's hypothesis for AlloNK's efficacy in autoimmune diseases is based on the 'readthrough' from its Phase 1/2 B-NHL clinical trial, where AlloNK in combination with rituximab demonstrated deep B-cell depletion and complete responses in heavily pre-treated patients, similar to the mechanism observed with autologous CD19 CAR T-cell therapy (auto-CAR-T) in autoimmune diseases.
Unlike auto-CAR-T, which is patient-specific, AlloNK is an 'off-the-shelf' allogeneic therapy, potentially offering greater accessibility and scalability, which could be a competitive advantage if efficacy and safety are proven.
The company acknowledges that its NK cell-based approach is unproven in autoimmune diseases, and these therapies may not prove competitive compared to existing treatments or other emerging cell therapies from competitors like Adicet Bio, Allogene Therapeutics, Bristol-Myers Squibb, Kyverna Therapeutics, and Novartis AG, who are also pursuing autoimmune indications.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Certificate of Incorporation Amendment	Amended and Restated Certificate of Incorporation dated July 22, 2024, authorizing 710,000,000 shares of capital stock (700M common, 10M preferred).	2024-07-22	Establishes the capital structure and includes provisions that may delay or discourage changes in control.
Bylaws Amendment	Amended and Restated Bylaws, including provisions for director removal, vacancy filling, board classification, and stockholder meeting requirements.		Reinforces corporate control mechanisms and may limit stockholder actions.
Equity Incentive Plan Adoption	Adopted the 2024 Equity Incentive Plan on July 22, 2024, as a successor to the 2020 Plan, authorizing 4,572,025 shares initially, with annual increases.	2024-07-22	Provides framework for equity compensation, but also introduces potential for future stockholder dilution through automatic share increases.
Equity Incentive Plan Amendment	Stockholders approved an increase to the 2024 Plan reserve by an additional 1,214,580 shares.	2025-06-24	Further expands the pool of shares available for equity awards, increasing potential future dilution.
Employee Stock Purchase Plan (ESPP) Adoption	Adopted the 2024 Employee Stock Purchase Plan in connection with the IPO, reserving 212,000 shares initially, with annual increases.		Provides employees with a mechanism to purchase shares, but also contributes to potential future dilution.
Corporate Social Responsibility Commitment	Committed to the Pledge 1% Movement campaign, reserving 84,556 shares of common stock for charitable purposes.	2021-07-01	Demonstrates corporate social responsibility, with a minor potential for future dilution upon issuance of these shares.
Delaware Law Application	Subject to Section 203 of the Delaware General Corporation Law, which prohibits certain business combinations with large stockholders.		Acts as an anti-takeover provision, potentially delaying or preventing changes in control.
Exclusive Forum Provisions	Amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain disputes and federal district courts for Securities Act claims.		Aims to centralize litigation, potentially limiting stockholders' ability to choose a preferred judicial forum and increasing costs for certain claims.

Legal Proceedings

Not currently a party to any litigation or legal proceedings that, in management's opinion, are likely to have a material adverse effect on the business.

Related Party Transactions

No license and development support-related revenue recognized from GC Cell for the three and six months ended June 30, 2025, compared to $0.3 million for the six months ended June 30, 2024.
Research and development expenses incurred with GC Cell for manufacturing services decreased significantly to $29 thousand for the six months ended June 30, 2025, from $1.5 million in the prior year period.
No expense reimbursements for development costs invoiced to GC Cell in connection with the AB-205 Agreement for the three and six months ended June 30, 2025, compared to $0.1 million for the six months ended June 30, 2024.
Incurred $31 thousand in research and development expenses for the six months ended June 30, 2025, for consulting services from Carnot Pharma, LLC, an entity controlled by RA Capital Management, L.P. (a stockholder affiliate).

Stakeholder Impact

Shareholders face increased risk of dilution from anticipated future capital raises and continued stock price volatility due to the early stage of development and financial losses.
Employees may benefit from increased headcount and stock-based compensation, but the company's ability to retain key personnel is a critical risk.
Patients with autoimmune diseases and cancers could potentially benefit from novel NK cell therapies if clinical trials are successful, but face risks associated with early-stage drug development, including adverse events and trial delays.
Collaborators like GC Cell continue their licensing and manufacturing agreements, indicating ongoing partnership, but the termination of the Affimed collaboration highlights partnership risks.
Creditors and investors face risks from the company's significant accumulated deficit and continued operating losses, necessitating future financing.

Next Steps

Report initial safety and translational data for AlloNK in combination with a monoclonal antibody across multiple autoimmune indications from ongoing clinical trials by the end of 2025.
Disclose the lead autoimmune indication for further development by the end of 2025.
Report initial clinical response data in the lead autoimmune indication from ongoing clinical trials with longer follow-up to inform registrational strategy in the first half of 2026.
Continue to invest in manufacturing capability and cryopreservation techniques to improve production and supply chain.
Seek additional funding through public or private equity/debt financings or strategic collaborations.

Key Dates

Date	Description
2019-02-14	Company incorporated in Delaware.
2019-09-01	Entered into an option and license agreement (Core Agreement) with GC Cell Corporation.
2019-11-01	Entered into a license agreement with GC Cell for AB-101 product candidate.
2020-03-01	Entered into a Master Agreement for Manufacturing Services with GC Cell.
2020-06-01	Adopted the 2020 Equity Incentive Plan.
2020-08-01	Entered into the GC Cell Research Services Agreement.
2020-10-01	Entered into a license agreement with GC Cell for AB-201 product candidate.
2021-02-01	Received a $30.0 million upfront payment from Merck Sharp & Dohme Corp.
2021-06-01	Clinical hold on Phase 1/2 AlloNK B-NHL clinical trial lifted.
2021-07-01	Board of directors approved reservation of 84,556 shares for Pledge 1% Movement commitment.
2022-08-01	Entered into a lease agreement for laboratory and vivarium space (Explora Lease).
2022-11-01	Entered into a strategic collaboration agreement with Affimed GmbH.
2022-12-01	Entered into a license agreement with GC Cell for AB-205 product candidate.
2023-01-01	Received Fast Track designation for AlloNK for IV infusion in combination with rituximab for the treatment of relapsed or refractory B-NHL.
2023-04-06	Board of directors approved a stock option repricing.
2023-09-01	Entered into an amendment to the AB-201 Agreement, granting back a license to GC Cell outside the Artiva Territory.
2023-12-01	GC Cell achieved the first regulatory milestone under the Amended AB-201 Agreement for first IND acceptance for AB-201 outside the Artiva Territory.
2024-02-01	Received Fast Track designation for AlloNK in combination with either rituximab or obinutuzumab to improve disease activity in patients with class III or class IV LN.
2024-04-01	2020 Equity Incentive Plan amended to increase total shares reserved.
2024-07-12	Effected a 1-for-4.386 reverse stock split of common stock and convertible preferred stock.
2024-07-18	Registration Statement on Form S-1 declared effective by the SEC.
2024-07-19	Common stock began trading on The Nasdaq Global Market.
2024-07-22	Completed Initial Public Offering (IPO) and adopted the 2024 Equity Incentive Plan.
2024-07-25	Underwriters partially exercised their 30-day option to purchase additional common stock from the IPO.
2024-11-01	Entered into a services agreement with Carnot Pharma, LLC.
2025-01-01	1,214,580 shares added to the 2024 Plan reserve and 242,916 shares added to the ESPP reserve.
2025-03-01	Entered into a lease agreement for a warehouse and storage facility (Eastgate Lease).
2025-05-01	Affimed filed for insolvency. Announced initiation of patient treatment with AlloNK in Phase 1/1b trial in SLE/LN (initiated late 2024).
2025-06-24	Stockholders approved an amendment to the 2024 Plan to increase the reserve by an additional 1,214,580 shares.
2025-06-30	End of the quarterly period covered by this report.
2025-07-01	Affimed Collaboration Agreement terminated.
2025-07-04	The One Big Beautiful Bill Act (OBBBA) was enacted in the U.S.
2025-07-01	Completed Phase 1/2 B-NHL clinical trial and discontinued remaining long-term follow-up period.
2025-08-06	Date the condensed financial statements were issued.
2025-08-01	Treated the first patient in the Phase 2a basket trial.
2025-12-31	Expected initial safety and translational data for AlloNK in autoimmune indications and disclosure of lead autoimmune indication for further development.
2026-06-30	Expected initial clinical response data in the lead autoimmune indication from ongoing clinical trials to inform registrational strategy.
2027-06-30	Expected liquidity runway into the second quarter of 2027.
2039-01-01	State net operating loss carryforwards begin to expire.

Recommendation

hold

The company is at a critical juncture, pivoting its lead asset, AlloNK, towards autoimmune indications, which is a high-risk, high-reward strategy given the novelty of cell therapies in this area. While the financial results show widening losses and increased cash burn, the cash runway into Q2 2027 provides some operational buffer. The termination of the Affimed collaboration is a setback, but the initiation of Phase 2a trials for AlloNK in autoimmune diseases is a positive clinical milestone. For existing investors, holding is advised to observe the upcoming clinical data readouts in late 2025 and early 2026, which will be crucial for validating the strategic shift. New investors should await more definitive clinical efficacy and safety data before considering an investment, given the significant uncertainties and the anticipated need for further dilutive capital raises.

Keywords

Biotechnology, NK cell therapy, AlloNK, Autoimmune disease, Systemic Lupus Erythematosus, Lupus Nephritis, Rheumatoid Arthritis, Sjogren's disease, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Clinical trials, SEC filing, 10-Q, Biopharmaceutical, Cell therapy, Immunotherapy, Drug development, Clinical stage, Orphan drug, Fast Track designation

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.